Prime Medicine, Inc.

NasdaqGM PRME

Prime Medicine, Inc. Total Assets for the quarter ending September 30, 2024: USD 332.78 M

Prime Medicine, Inc. Total Assets is USD 332.78 M for the quarter ending September 30, 2024, a 39.16% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.

Prime Medicine, Inc. Total Assets for the quarter ending September 30, 2023 was USD 239.15 M, a 11.09% change year over year.
Prime Medicine, Inc. Total Assets for the quarter ending September 30, 2022 was USD 215.26 M, a -31.70% change year over year.
Prime Medicine, Inc. Total Assets for the quarter ending September 30, 2021 was USD 315.19 M.

Key data

Date	Total Assets	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity

NasdaqGM: PRME

Prime Medicine, Inc.

CEO	Dr. Keith Michael Gottesdiener M.D., Ph.D.
IPO Date	Oct. 20, 2022
Location	United States
Headquarters	21 Erie Street
Employees	234
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years